Peptides. Your brand.
Ready for what comes next.
You bring the customers and the category knowledge. We bring U.S.-based pharmacy partners, licensed providers and the platform behind your brand. Prepare now for selected prescription peptide programs, with launch dependent on applicable FDA policy and pharmacy requirements.
White-label peptide telehealth planning means preparing a branded patient experience and operating model before opening any selected pending program. TEHR peptide programs remain pending; not open for prescribing or fulfillment.
You bring the vision.
We bring everything else.
The infrastructure and partners are in place. TEHR helps you prepare the brand experience, patient intake, provider workflows and pharmacy coordination so you can move quickly as eligible peptide programs become available. Licensed clinicians assess patients and prescribe only when clinically appropriate. Each product must meet applicable regulatory, pharmacy and state requirements before launch.
You keep your identity. You keep your patient relationships. You keep your economics. We make the machine run.
Map your next movePeptides.
Ready for what’s next.
U.S.-based pharmacies.
Licensed providers. Your brand.
Our infrastructure and partners are in place for selected prescription peptide programs. We’re preparing to launch quickly when applicable FDA policy permits and pharmacy requirements are met.
What does “pending” mean?
As of October 20, 2026, the federal government lists the “Interim Access Policy for Compounding Using Certain Peptides” as pending regulatory review. A committee recommendation or pending policy does not itself establish that a specific product can launch. Each program must meet the applicable requirements.
Compounded medications are not FDA-approved. U.S. pharmacy dispensing and a provider’s prescription do not change that distinction.
View the government policy record FDA information on compounded medicationsChoose your categories.
Choose the categories that fit your people. Expand when you’re ready. The infrastructure is already built.
The next peptide chapter. Be ready for it.
U.S.-based pharmacy partners. Licensed providers. Your brand. TEHR has the infrastructure and partners in place for selected prescription peptide programs, with rapid rollout planned when applicable FDA policy permits and pharmacy requirements are met.
Plan your peptide launchCategory availability depends on the specific product, regulatory requirements, state, pharmacy and clinical eligibility. Selected peptide programs are in preparation and are not available for prescribing or fulfillment until applicable requirements are met. Clinical decisions remain with independent licensed providers.
Your brand.
Powered by TEHR.
Every telehealth brand you envy runs on infrastructure you cannot see. TEHR is that infrastructure. All of it wearing your brand.
Your brand, from the first click
Storefront, intake, patient portal and communications come together around your identity. You keep your brand and the relationships you’ve built.
Licensed clinicians run the medicine
Independent licensed providers deliver clinical care and make prescribing decisions. TEHR supplies the technology and administrative infrastructure around that care.
AI that supports the team
AI-assisted intake and chart preparation help the clinical team organize information, with clinicians reviewing the work and remaining in control.
Google Calendar, connected
Providers can optionally connect Google Calendar to sync appointments from TEHR. Creating, rescheduling or cancelling an appointment in TEHR creates, updates or removes the matching event. Providers can disconnect at any time. Read the Google Calendar disclosure.
An operation that stays connected
Pharmacy coordination, lab workflows, payments, subscriptions and patient notifications support the journey behind the scenes. Dedicated Patient Support Coordinators are available as an optional add-on.
You run the brand. Licensed clinicians run the medicine.
Priced like a partner,
not a percentage.
A platform subscription based on the categories you offer, plus a flat fee per patient transaction. TEHR does not take a percentage of your revenue.
Common questions.
How does white-label telehealth work for peptide operators?
White-label peptide telehealth planning means preparing a branded patient experience and operating model before opening any selected pending program. TEHR peptide programs remain pending; not open for prescribing or fulfillment.
Do I need a medical license to launch a telehealth brand?
You do not need to personally provide medical care to build a health brand. Ownership and management structures depend on state law and your operating model; independent licensed providers must control clinical decisions. Read our brand ownership guide.
Are prescription peptide programs live?
Selected TEHR peptide programs are pending; not open for prescribing or fulfillment. Infrastructure and U.S.-based pharmacy relationships support readiness, while product-specific regulatory, pharmacy and clinical requirements determine whether a program can launch. See peptide launch readiness.
Does TEHR take a revenue share?
No. TEHR uses a flat platform subscription plus a flat transaction fee, with 0% revenue share. Your proposal identifies included services and any additional clinical, pharmacy, lab, payment-processing or support costs.
Bring the audience you built. Plan your next move.
30 minutes. Your vision. Our platform. We’ll map your audience, show you the experience and talk through whether there’s a fit.